| Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer E Castro, C Goh, D Olmos, E Saunders, D Leongamornlert, ... Journal of Clinical Oncology 31 (14), 1748, 2013 | 899 | 2013 |
| Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up C Parker, E Castro, K Fizazi, A Heidenreich, P Ost, G Procopio, B Tombal, ... Annals of Oncology 31 (9), 1119-1134, 2020 | 686 | 2020 |
| BRCA2 is a moderate penetrance gene contributing to young-onset prostate cancer: implications for genetic testing in prostate cancer patients Z Kote-Jarai, D Leongamornlert, E Saunders, M Tymrakiewicz, E Castro, ... British journal of cancer 105 (8), 1230-1234, 2011 | 459 | 2011 |
| Germline BRCA1 mutations increase prostate cancer risk D Leongamornlert, N Mahmud, M Tymrakiewicz, E Saunders, T Dadaev, ... British journal of cancer 106 (10), 1697-1701, 2012 | 394 | 2012 |
| Effect of BRCA mutations on metastatic relapse and cause-specific survival after radical treatment for localised prostate cancer E Castro, C Goh, D Leongamornlert, E Saunders, M Tymrakiewicz, ... European urology 68 (2), 186-193, 2015 | 373 | 2015 |
| Genome-Wide Association Study in BRCA1 Mutation Carriers Identifies Novel Loci Associated with Breast and Ovarian Cancer Risk FJ Couch, X Wang, L McGuffog, A Lee, C Olswold, KB Kuchenbaecker, ... PLoS genetics 9 (3), e1003212, 2013 | 331 | 2013 |
| PROREPAIR-B: a prospective cohort study of the impact of germline DNA repair mutations on the outcomes of patients with metastatic castration-resistant prostate cancer E Castro, N Romero-Laorden, A Del Pozo, R Lozano, A Medina, J Puente, ... Journal of Clinical Oncology 37 (6), 490-503, 2019 | 330 | 2019 |
| The genetic epidemiology of prostate cancer and its clinical implications R Eeles, C Goh, E Castro, E Bancroft, M Guy, AAA Olama, D Easton, ... Nature reviews Urology 11 (1), 18-31, 2014 | 322 | 2014 |
| Targeted prostate cancer screening in BRCA1 and BRCA2 mutation carriers: results from the initial screening round of the IMPACT study EK Bancroft, EC Page, E Castro, H Lilja, A Vickers, D Sjoberg, M Assel, ... European urology 66 (3), 489-499, 2014 | 291 | 2014 |
| DNA repair in prostate cancer: biology and clinical implications J Mateo, G Boysen, CE Barbieri, HE Bryant, E Castro, PS Nelson, ... European urology 71 (3), 417-425, 2017 | 225 | 2017 |
| Interim results from the IMPACT study: evidence for prostate-specific antigen screening in BRCA2 mutation carriers EC Page, EK Bancroft, MN Brook, M Assel, MH Al Battat, S Thomas, ... European urology 76 (6), 831-842, 2019 | 217 | 2019 |
| The role of BRCA1 and BRCA2 in prostate cancer E Castro, R Eeles Asian journal of andrology 14 (3), 409, 2012 | 214 | 2012 |
| Talazoparib monotherapy in metastatic castration-resistant prostate cancer with DNA repair alterations (TALAPRO-1): an open-label, phase 2 trial JS de Bono, N Mehra, GV Scagliotti, E Castro, T Dorff, A Stirling, A Stenzl, ... The Lancet Oncology 22 (9), 1250-1264, 2021 | 202 | 2021 |
| Prevalence of malnutrition and nutritional characteristics of patients with inflammatory bowel disease MJ Casanova, M Chaparro, B Molina, O Merino, R Batanero, ... Journal of Crohn's and Colitis 11 (12), 1430-1439, 2017 | 189 | 2017 |
| mTORC1-dependent AMD1 regulation sustains polyamine metabolism in prostate cancer A Zabala-Letona, A Arruabarrena-Aristorena, N Martín-Martín, ... Nature 547 (7661), 109-113, 2017 | 181 | 2017 |
| Prognostic value of blood mRNA expression signatures in castration-resistant prostate cancer: a prospective, two-stage study D Olmos, D Brewer, J Clark, DC Danila, C Parker, G Attard, M Fleisher, ... The lancet oncology 13 (11), 1114-1124, 2012 | 132 | 2012 |
| Niraparib and abiraterone acetate for metastatic castration-resistant prostate cancer KN Chi, D Rathkopf, MR Smith, E Efstathiou, G Attard, D Olmos, JY Lee, ... Journal of Clinical Oncology 41 (18), 3339-3351, 2023 | 130 | 2023 |
| Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trial MR Smith, HI Scher, S Sandhu, E Efstathiou, PN Lara, YY Evan, ... The Lancet Oncology 23 (3), 362-373, 2022 | 127 | 2022 |
| Identification of a novel prostate cancer susceptibility variant in the KLK3 gene transcript Z Kote-Jarai, A Amin Al Olama, D Leongamornlert, M Tymrakiewicz, ... Human genetics 129, 687-694, 2011 | 123 | 2011 |
| Evolution after anti-TNF discontinuation in patients with inflammatory bowel disease: a multicenter long-term follow-up study MJ Casanova, M Chaparro, V García-Sánchez, O Nantes, E Leo, ... Official journal of the American College of Gastroenterology| ACG 112 (1 …, 2017 | 117 | 2017 |
